Jefferies Financial Group Comments on Establishment Labs Holdings Inc.’s FY2022 Earnings (NASDAQ:ESTA)

Establishment Labs Holdings Inc. (NASDAQ:ESTAGet Rating) – Equities research analysts at Jefferies Financial Group reduced their FY2022 earnings per share (EPS) estimates for shares of Establishment Labs in a report issued on Tuesday, May 10th. Jefferies Financial Group analyst Z. Weiner now forecasts that the company will post earnings per share of ($1.24) for the year, down from their prior forecast of ($1.20). Jefferies Financial Group also issued estimates for Establishment Labs’ Q4 2022 earnings at ($0.35) EPS and FY2023 earnings at ($0.69) EPS.

Establishment Labs (NASDAQ:ESTAGet Rating) last released its quarterly earnings results on Monday, May 9th. The company reported ($0.24) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.42) by $0.18. Establishment Labs had a negative return on equity of 66.46% and a negative net margin of 29.77%. During the same quarter in the previous year, the firm posted ($0.29) earnings per share.

ESTA has been the subject of a number of other reports. Zacks Investment Research upgraded Establishment Labs from a “sell” rating to a “hold” rating in a report on Tuesday. BTIG Research raised their target price on Establishment Labs from $95.00 to $110.00 and gave the company a “buy” rating in a report on Friday, April 22nd. Cowen increased their price target on Establishment Labs from $95.00 to $125.00 in a research report on Friday, April 22nd. The Goldman Sachs Group reduced their price target on Establishment Labs from $78.00 to $67.00 and set a “neutral” rating on the stock in a research report on Monday, March 21st. Finally, Cowen increased their price target on Establishment Labs from $95.00 to $125.00 in a research report on Friday, April 22nd. Two research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Buy” and a consensus price target of $98.86.

Shares of Establishment Labs stock opened at $55.54 on Friday. The business has a 50-day moving average of $66.51 and a 200 day moving average of $63.78. Establishment Labs has a 12 month low of $46.93 and a 12 month high of $93.80. The stock has a market capitalization of $1.34 billion, a price-to-earnings ratio of -31.55 and a beta of 1.08. The company has a debt-to-equity ratio of 1.02, a current ratio of 3.55 and a quick ratio of 2.66.

Several institutional investors and hedge funds have recently bought and sold shares of the company. Madryn Asset Management LP acquired a new position in Establishment Labs during the fourth quarter worth approximately $49,475,000. Cowen AND Company LLC increased its holdings in shares of Establishment Labs by 61.6% in the 3rd quarter. Cowen AND Company LLC now owns 623,687 shares of the company’s stock valued at $44,644,000 after acquiring an additional 237,640 shares during the period. American Century Companies Inc. purchased a new stake in Establishment Labs in the 1st quarter valued at $14,516,000. Millennium Management LLC boosted its stake in Establishment Labs by 69.8% during the 4th quarter. Millennium Management LLC now owns 514,821 shares of the company’s stock worth $34,797,000 after purchasing an additional 211,677 shares during the period. Finally, Barclays PLC grew its position in Establishment Labs by 20,497.5% during the 4th quarter. Barclays PLC now owns 180,640 shares of the company’s stock worth $12,210,000 after purchasing an additional 179,763 shares during the last quarter. Institutional investors and hedge funds own 77.79% of the company’s stock.

In related news, major shareholder Jw Asset Management, Llc acquired 10,000 shares of the business’s stock in a transaction on Monday, February 28th. The shares were bought at an average price of $59.42 per share, with a total value of $594,200.00. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Insiders purchased 70,000 shares of company stock valued at $4,443,300 over the last ninety days. 13.08% of the stock is currently owned by corporate insiders.

About Establishment Labs (Get Rating)

Establishment Labs Holdings Inc, a medical technology company, manufactures and markets medical devices for aesthetic and reconstructive plastic surgery. The company primarily offers silicone gel-filled breast implants under Motiva Implants brand name. It also provides Motiva Ergonomix and Motiva Ergonomix2 gravity sensitive round soft silicone-gel-filled breast implants; and Motiva Flora Tissue Expander, a breast tissue expander, as well as distributes Puregraft line of products for autologous adipose tissue harvesting and redistribution.

Recommended Stories

Earnings History and Estimates for Establishment Labs (NASDAQ:ESTA)

Receive News & Ratings for Establishment Labs Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Establishment Labs and related companies with's FREE daily email newsletter.